Notícias

Can-Fite BioPharma Ltd. (NYSE:CANF) reported extended survival trends in a key late-stage cancer trial alongside a $4 million warrant exercise agreement to fund ongoing clinical operations. • Can Fite Biopharma stock is at significant support. What is going on with CANF? Phase 3 Liver Cancer Trial Progress The clinical-stage biotechnology company observed longer-than-expected blinded overall survival in its ongoing pivotal Phase 3 trial evaluating Namodenoson for advanced hepatocellular carcinom

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index up 0.1% and t

Can-Fite stock jumps 20% after mid-stage data show namodenoson is well tolerated in advanced pancreatic cancer patients, meeting the study's primary safety endpoint.

Health care stocks were edging up late Friday afternoon with the NYSE Health Care Index and the Stat

Health care stocks declined Friday afternoon, with the NYSE Health Care Index and the State Street H

All three major US stock indexes were edging lower in midday trading on Friday following the Christm

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.6% and the actively tr